Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$10.72 +1.4%	$8.60	$4.24 ▼ $14.44	$921.16M	0.72	1.19 million shs	800,367 shs
BCAX Bicara Therapeutics	$9.07 -1.4%	$11.54	$7.80 ▼ $28.09	$492.46M	N/A	601,182 shs	248,783 shs
MDWD MediWound	$19.47 +1.8%	$19.76	$14.14 ▼ $22.51	$209.02M	0.32	71,329 shs	10,185 shs
XNCR Xencor	$8.41 +1.3%	$8.71	$7.16 ▼ $27.24	$599.26M	0.85	680,928 shs	306,907 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	0.00%	+13.08%	+37.79%	+30.89%	+160.19%
BCAX Bicara Therapeutics	0.00%	+4.18%	-17.73%	-14.15%	+907,399,900.00%
MDWD MediWound	0.00%	+1.09%	-10.15%	+30.06%	+34.18%
XNCR Xencor	0.00%	+3.26%	-7.84%	-3.28%	-54.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVXL Anavex Life Sciences	3.6022 of 5 stars	3.7	0.0	4.7	1.4	0.8	0.6
BCAX Bicara Therapeutics	1.3921 of 5 stars	3.5	0.0	0.0	0.0	0.8	0.6
MDWD MediWound	1.303 of 5 stars	3.5	1.0	0.0	0.0	0.8	0.6
XNCR Xencor	4.0045 of 5 stars	3.4	2.0	3.9	1.9	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	3.33	Buy	$44.00	310.45% Upside
BCAX Bicara Therapeutics	3.00	Buy	$31.86	251.10% Upside
MDWD MediWound	3.00	Buy	$31.80	63.33% Upside
XNCR Xencor	2.75	Moderate Buy	$28.00	233.14% Upside

Current Analyst Ratings Breakdown

Latest MDWD, BCAX, XNCR, and AVXL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00
5/23/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$8.00
5/23/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
5/22/2025	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00 ➝ $31.00
5/16/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $41.00
5/8/2025	XNCR Xencor	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$22.00 ➝ $6.00
5/2/2025	MDWD MediWound	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
4/30/2025	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$31.00
4/21/2025	XNCR Xencor	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/17/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underweight	$8.00
4/7/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$9.04 per share	N/A
MDWD MediWound	$20.22M	10.41	N/A	N/A	$2.89 per share	6.74
XNCR Xencor	$110.49M	5.41	N/A	N/A	$9.63 per share	0.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-40.93%	-36.38%	8/5/2025 (Estimated)
BCAX Bicara Therapeutics	-$68M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/12/2025 (Estimated)
MDWD MediWound	-$30.22M	-$2.09	N/A	N/A	N/A	-110.45%	-74.12%	-30.92%	8/13/2025 (Estimated)
XNCR Xencor	-$232.62M	-$3.06	N/A	N/A	N/A	-181.17%	-31.94%	-22.19%	8/4/2025 (Estimated)

Latest MDWD, BCAX, XNCR, and AVXL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	-$0.07	+$0.58	-$0.07	$5.20 million	$3.96 million
5/13/2025	Q2 2025	AVXL Anavex Life Sciences	-$0.16	-$0.13	+$0.03	-$0.13	N/A	N/A
5/13/2025	Q1 2025	BCAX Bicara Therapeutics	-$0.40	-$0.68	-$0.28	-$0.68	N/A	N/A
5/8/2025	Q1 2025	XNCR Xencor	-$0.60	-$0.66	-$0.06	-$0.66	$23.44 million	$32.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	6.74	6.74
BCAX Bicara Therapeutics	N/A	24.62	24.62
MDWD MediWound	N/A	2.15	1.99
XNCR Xencor	0.16	5.89	5.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
BCAX Bicara Therapeutics	N/A
MDWD MediWound	46.83%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.00%
BCAX Bicara Therapeutics	N/A
MDWD MediWound	9.20%
XNCR Xencor	5.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	85.37 million	75.98 million	Optionable
BCAX Bicara Therapeutics	32	54.54 million	N/A	N/A
MDWD MediWound	80	10.81 million	9.81 million	Optionable
XNCR Xencor	280	71.17 million	67.45 million	Optionable

MDWD, BCAX, XNCR, and AVXL Headlines

Recent News About These Companies

Xencor, Inc. (NASDAQ:XNCR) Receives $28.00 Consensus PT from Brokerages

July 6 at 3:45 AM | americanbankingnews.com

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of "Moderate Buy" by Analysts

July 3 at 2:43 AM | marketbeat.com

Xencor, Inc. (XNCR) Latest Stock News & Headlines - Yahoo Finance

June 29, 2025 | ca.finance.yahoo.com

Xencor (NASDAQ:XNCR) Shares Down 5.7% on Insider Selling

June 17, 2025 | marketbeat.com

Insider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,215 Shares of Stock

June 17, 2025 | insidertrades.com

Insider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,215 Shares of Stock

June 16, 2025 | marketbeat.com

Kurt A. Gustafson Sells 2,993 Shares of Xencor, Inc. (NASDAQ:XNCR) Stock

June 16, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Director Sells $27,595.46 in Stock

June 16, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Director Ellen Feigal Sells 2,993 Shares

June 16, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Trading Up 6.3% - Here's What Happened

June 10, 2025 | marketbeat.com

Bank of America Corp DE Sells 585,930 Shares of Xencor, Inc. (NASDAQ:XNCR)

June 9, 2025 | marketbeat.com

27,491 Shares in Xencor, Inc. (NASDAQ:XNCR) Acquired by Wellington Management Group LLP

June 8, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages

June 8, 2025 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)

May 13, 2025 | theglobeandmail.com

Xencor Reports First Quarter 2025 Financial Results

May 7, 2025 | uk.finance.yahoo.com

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

May 7, 2025 | zacks.com

Xencor, Inc. (NASDAQ:XNCR) EVP Nancy Valente Sells 4,616 Shares

May 7, 2025 | insidertrades.com

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

May 1, 2025 | zacks.com

William Blair starts Xencor stock with Outperform rating

April 23, 2025 | uk.investing.com

William Blair Initiates Coverage of Xencor (XNCR) with Outperform Recommendation

April 22, 2025 | msn.com

Xencor initiated with an Outperform at William Blair

April 21, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD, BCAX, XNCR, and AVXL Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$10.72 +0.15 (+1.42%)

Closing price 07/3/2025 03:48 PM Eastern

Extended Trading

$10.70 -0.02 (-0.19%)

As of 07/3/2025 04:58 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Bicara Therapeutics NASDAQ:BCAX

$9.07 -0.13 (-1.37%)

Closing price 07/3/2025 01:34 PM Eastern

Extended Trading

$9.17 +0.10 (+1.10%)

As of 07/3/2025 04:01 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

MediWound NASDAQ:MDWD

$19.47 +0.35 (+1.83%)

Closing price 07/3/2025 03:05 PM Eastern

Extended Trading

$19.32 -0.15 (-0.77%)

As of 07/3/2025 04:01 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Xencor NASDAQ:XNCR

$8.40 +0.11 (+1.27%)

Closing price 07/3/2025 01:23 PM Eastern

Extended Trading

$8.40 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time